All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-18T13:46:38.000Z

EHA 2019 | ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM

By Emily Smith, Paul Richardson
Jun 18, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, speaks to the Multiple Myeloma Hub about the results of the phase III ICARIA-MM trial of isatuximab + pomalidomide + dexamethasone compared to standard-of-care - pomalidomide + dexamethasone - for patients with relapsed/refractory multiple myeloma (RRMM).

 
Prof. Richardson highlights the high quality responses to the triplet regimen in relation to overall response and the primary endpoint of progression-free survival (approximately 12 months versus 6 months).
 
It was also highlighted that the triplet regimen was well tolerated and did not reduce the patient's quality of life. Whilst there was a higher rate of infection in the triplet arm, these were manageable. In subgroup analysis, all subgroups benefited.
 
Comparing isatuximab to daratumumab, Prof. Richardson highlighted some of the differences, including isatuximab's higher specificity to a different epitope, enhancing the apoptotic signal and leading to less complement activation and therefore less infusion reactions. Additionally, this means isatuximab can be given to patients with chronic obstructive pulmonary disease (COPD) and asthma which is significant.

ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM

More about...
DexamethasoneEHAEHA 2019ICARIA-MMIsatuximabPomalidomideRelapsed/refractory multiple myeloma

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 42 days left ...

Related articles

Add bookmark

EHA 2019 | Updated analysis of the HORIZON phase II trial: Melflufen + dexamethasone for RRMM

This study investigated the efficacy and safety of melflufen and dexamethasone in patients with relapsed or refractory multiple myeloma.

Jun 25, 2019
Add bookmark

EHA 2019 | Updated analysis of the HORIZON phase II trial: Melflufen + dexamethasone for RRMM

This study investigated the efficacy and safety of melflufen and dexamethasone in patients with relapsed...

Jun 25, 2019
Add bookmark

ASCO 2019 | ICARIA MM: Isatuximab + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma: phase III results

Phase III data from the ICARIA MM study group trial, which investigated the safety and efficacy of isatuximab (Isa),...

Jun 11, 2019
Add bookmark

ASCO 2019 | ICARIA MM: Isatuximab + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma: phase III results

Phase III data from the ICARIA MM study group trial, which investigated the...

Jun 11, 2019

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox